Bioresorbable Scaffold-Based Controlled Drug Delivery for Restenosis
- PMID: 30367355
- DOI: 10.1007/s12265-018-9841-x
Bioresorbable Scaffold-Based Controlled Drug Delivery for Restenosis
Abstract
Bioresorbable scaffolds have emerged as a potential alternative to non-erodible metal implants to alleviate the long-term risk of permanent device vascular implant-related adverse events. Bioresorbable scaffolds provide a temporary mechanical support function until the vessel reaches complete healing, and the implant progressively disappears and vasomotion resumes. A polymer matrix with embedded drugs coated onto the scaffold surface degrades slowly, reducing the size from the exterior toward the interior, and this allows controlled drug release to a local vascular segment. Drug elution from a bioresorbable scaffold system is characterized by a rapid initial release that achieves high concentration along the intimal surface, which is designed to prevail vascular dilation-induced injury and formation of neointimal hyperplasia. This review highlights diverse types of bioresorbable biomaterials as vascular scaffolds, drug release kinetics, adaptive arterial wall remodeling, and complexities in the advancement of vascular scaffolds to treat restenosis.
Keywords: Biocorrodible metallic scaffolds; Bioresorbable polymer scaffolds; Drug distribution; Drug release kinetics; Restenosis; Vascular remodeling.
Similar articles
-
Bioresorbable vascular scaffolds: Biodegradation, drug delivery and vascular remodeling.Pharmacol Res. 2016 May;107:163-171. doi: 10.1016/j.phrs.2016.03.020. Epub 2016 Mar 18. Pharmacol Res. 2016. PMID: 27001225 Review.
-
Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Arteries Below the Knee: 12-Month Clinical and Imaging Outcomes.JACC Cardiovasc Interv. 2016 Aug 22;9(16):1721-8. doi: 10.1016/j.jcin.2016.06.005. JACC Cardiovasc Interv. 2016. PMID: 27539693
-
Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.JACC Cardiovasc Interv. 2016 Mar 28;9(6):565-74. doi: 10.1016/j.jcin.2015.12.004. JACC Cardiovasc Interv. 2016. PMID: 27013155 Clinical Trial.
-
Bioresorbable Scaffold: The Emerging Reality and Future Directions.Circ Res. 2017 Apr 14;120(8):1341-1352. doi: 10.1161/CIRCRESAHA.117.310275. Circ Res. 2017. PMID: 28408454 Review.
-
Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.JACC Cardiovasc Interv. 2017 Jun 12;10(11):1115-1130. doi: 10.1016/j.jcin.2017.03.015. Epub 2017 May 17. JACC Cardiovasc Interv. 2017. PMID: 28527768 Clinical Trial.
Cited by
-
Adventitial injection of HA/SA hydrogel loaded with PLGA rapamycin nanoparticle inhibits neointimal hyperplasia in a rat aortic wire injury model.Drug Deliv Transl Res. 2022 Dec;12(12):2950-2959. doi: 10.1007/s13346-022-01158-x. Epub 2022 Apr 4. Drug Deliv Transl Res. 2022. PMID: 35378720
-
Bioprinting for combating infectious diseases.Bioprinting. 2020 Dec;20:e00104. doi: 10.1016/j.bprint.2020.e00104. Epub 2020 Sep 28. Bioprinting. 2020. PMID: 33015403 Free PMC article. Review.
-
Inhibition of ERK or Akt ameliorates intimal hyperplasia via up-regulation of Cx37 and down-regulation of Cx43 in balloon injury rat model.Cardiovasc Diagn Ther. 2020 Aug;10(4):658-666. doi: 10.21037/cdt-20-345. Cardiovasc Diagn Ther. 2020. PMID: 32968622 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical